New drug aims to stop immune attack after stem cell transplants
NCT ID NCT07246031
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC2001 along with standard care. The goal is to see if the drug reduces the risk of aGVHD and is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BPC2001 (also known as KRN-7000)
- What this could lead to
- If it works, this could point toward a new way to prevent a serious complication of stem cell transplants, making the procedure safer for more patients.
- What could go wrong
- This is an early phase 2b trial with only 50 participants, so results may not apply to everyone. The drug could cause side effects or fail to reduce graft-versus-host disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can donor immune cells tame stem cell transplant risks?